Avalo Therapeutics (AVTX) exhibits a high degree of equity volatility, which is characteristic of clinical-stage micro-cap and small-cap biotechnology stocks trading on public exchanges. The stock typically features an elevated beta coefficient significantly above market averages, meaning its share price reacts sharply to clinical trial data announcements, regulatory updates, pipeline milestones, and broader sentiment shifts across the biotechnology sector.